PR Newswire
NASHVILLE, Tenn., Nov. 7, 2018
NASHVILLE, Tenn., Nov. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals
Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2018 financial results after the market closes on
Tuesday, November 13, 2018. A conference call and live Internet webcast will be held on
Tuesday, November 13, 2018, at 4:30 p.m. Eastern Time to discuss the
results.
To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A
rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers)
or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 4258737. The live webcast and
rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality
prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute
care, gastroenterology, and oncology market segments.
The Company's portfolio of FDA approved brands includes:
- Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic
and acute constipation;
- Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori
(H. pylori) infection and related duodenal ulcer disease;
- Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with
euvolemic and hypervolemic hyponatremia;
- Ethyol® (amifostine) Injection, for the reduction of xerostomia (dry mouth) in patients undergoing
post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of
cisplatin in patients with advanced ovarian cancer;
- Totect® (dexrazoxane hydrochloride) Injection, for emergency oncology intervention, to treat the
toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues).
Cumberland's pipeline of product candidates includes:
- Hepatoren® (ifetroban) Injection, a Phase II candidate for the treatment of critically ill
patients suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS");
- Boxaban® (ifetroban) Oral Capsules, a Phase II candidate for the treatment of asthma patients with
aspirin-exacerbated respiratory disease ("AERD");
- Vasculan® (ifetroban) Oral Capsules, a Phase II candidate for the treatment of patients with
systemic sclerosis (SSc) form of autoimmune disease;
- Portaban® (ifetroban) Injection and Oral Capsules, a Phase II candidate for the treatment of
patients with portal hypertension associated with liver disease;
- RediTrex™ (methotrexate) Injection, an approval submission candidate for the treatment of active
rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.
For more information on Cumberland's approved products, including full prescribing
information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2018-financial-results-300745891.html
SOURCE Cumberland Pharmaceuticals Inc.